Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2025-09-12

Clinical Trial Update: A Study to Assess the Efficacy and Safety of Namilumab in Participants With Chronic Pulmonary Sarcoidosis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating namilumab for chronic pulmonary sarcoidosis was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Namilumab (namilumab)

Snippet

Sponsor: Kinevant Sciences GmbH | Conditions: Sarcoidosis, Pulmonary | Phase 2 | Status: TERMINATED | Results posted: 2025-09-12